Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations.

Patel JV, Caslake MJ, Vyas A, Cruickshank JK, Prabhakaran D, Bhatnagar D, Reddy KS, Lip GY, Mackness MI, Hughes EA, Durrington PN.

Atherosclerosis. 2010 Apr;209(2):579-84. doi: 10.1016/j.atherosclerosis.2009.10.010. Epub 2009 Oct 13.

PMID:
19922937
2.

No influence of increased intake of orange and blackcurrant juices and dietary amounts of vitamin E on paraoxonase-1 activity in patients with peripheral arterial disease.

Dalgård C, Christiansen L, Jonung T, Mackness MI, de Maat MP, Hørder M.

Eur J Nutr. 2007 Sep;46(6):354-63. Epub 2007 Aug 21.

PMID:
17712585
3.

The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status.

Domagała TB, Łacinski M, Trzeciak WH, Mackness B, Mackness MI, Jakubowski H.

Cell Mol Biol (Noisy-le-grand). 2006 Dec 31;52(5):4-10.

PMID:
17543199
4.

Paraoxonase gene polymorphism and serum activity in progressive IgA nephropathy.

Kovács TJ, Harris S, Vas TK, Seres I, Short CD, Wittmann IK, Paragh G, Mackness MI, Mackness B, Durrington PN, Nagy JM, Brenchley PE.

J Nephrol. 2006 Nov-Dec;19(6):732-8.

PMID:
17173245
5.
6.

Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India.

Patel JV, Vyas A, Cruickshank JK, Prabhakaran D, Hughes E, Reddy KS, Mackness MI, Bhatnagar D, Durrington PN.

Atherosclerosis. 2006 Apr;185(2):297-306. Epub 2005 Jul 7.

PMID:
16005463
7.

Paraoxonase polymorphisms and self-reported chronic ill-health in farmers dipping sheep.

Povey AC, Mackness MI, Durrington PN, Dippnall M, Smith AE, Mackness B, Cherry NM.

Occup Med (Lond). 2005 Jun;55(4):282-6.

PMID:
15982977
8.

Paraoxonase 1 status in the Thai population.

Phuntuwate W, Suthisisang C, Koanantakul B, Mackness MI, Mackness B.

J Hum Genet. 2005;50(6):293-300. Epub 2005 May 28.

PMID:
15924216
9.

Nonesterified fatty acids as mediators of glucose intolerance in Indian Asian populations.

Patel JV, Vyas A, Prabhakaran D, Bhatnagar D, Durrington PN, Heald A, Hughes EA, Mackness MI, Reddy KS, Cruickshank JK.

Diabetes Care. 2005 Jun;28(6):1505-7. No abstract available.

PMID:
15920081
10.

Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy.

Kwok S, Selby PL, McElduff P, Laing I, Mackness B, Mackness MI, Prais H, Morgan J, Yates AP, Durrington PN, Sci FM.

Clin Endocrinol (Oxf). 2004 Dec;61(6):760-7.

PMID:
15579192
11.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators.

Lancet. 2004 Aug 21-27;364(9435):685-96.

PMID:
15325833
12.

Paraoxonase polymorphisms and coronary heart disease.

Durrington PN, Mackness B, Mackness MI.

Lancet. 2004 Aug 14-20;364(9434):579-80; author reply 580. No abstract available.

PMID:
15313350
13.

The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention.

Mackness MI, Durrington PN, Mackness B.

Am J Cardiovasc Drugs. 2004;4(4):211-7. Review.

PMID:
15285696
14.

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.

Thomason MJ, Colhoun HM, Livingstone SJ, Mackness MI, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Fuller JH; CARDS Investigators.

Diabet Med. 2004 Aug;21(8):901-5.

PMID:
15270795
15.

Isolation of plasma small-dense low-density lipoprotein using a simple air-driven ultracentrifuge and quantification using immunoassay of apolipoprotein B.

Menys VC, Liu Y, Mackness MI, Kwok S, Caslake MJ, Stewart G, Durrington PN.

Clin Chem Lab Med. 2004 Jan;42(1):30-6.

PMID:
15061377
16.

Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure.

Hernández AF, Mackness B, Rodrigo L, López O, Pla A, Gil F, Durrington PN, Pena G, Parrón T, Serrano JL, Mackness MI.

Hum Exp Toxicol. 2003 Nov;22(11):565-74.

PMID:
14686479
17.

Measurement of plasma small-dense LDL concentration by a simplified ultracentrifugation procedure and immunoassay of apolipoprotein B.

Menys VC, Liu Y, Mackness MI, Caslake MJ, Kwok S, Durrington PN.

Clin Chim Acta. 2003 Aug;334(1-2):95-106.

PMID:
12867279
18.

Paraoxonase in Persian Gulf War veterans.

Hotopf M, Mackness MI, Nikolaou V, Collier DA, Curtis C, David A, Durrington P, Hull L, Ismail K, Peakman M, Unwin C, Wessely S, Mackness B.

J Occup Environ Med. 2003 Jul;45(7):668-75.

PMID:
12855907
19.

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.

Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, Fuller JH, Julier K, Mackness MI, Neil HA; CARDS Investigators.

Atherosclerosis. 2003 Apr;167(2):243-55.

PMID:
12818407
20.

Paraoxonase and coronary heart disease.

Mackness MI, Mackness B, Durrington PN.

Atheroscler Suppl. 2002 Dec;3(4):49-55. Review.

PMID:
12573363
21.

Appropriate body-mass index for Asians.

Patel JK, Hughes EA, Mackness MI, Vyas A, Cruickshank JK.

Lancet. 2003 Jan 4;361(9351):85. No abstract available.

PMID:
12517508
22.

Clinical, biochemical, and immunohistochemical features of necrobiotic xanthogranulomatosis.

Jeziorska M, Hassan A, Mackness MI, Woolley DE, Tullo AB, Lucas GS, Durrington PN.

J Clin Pathol. 2003 Jan;56(1):64-8.

23.

The hunt for nutritional and pharmacological modulators of paraoxonase.

Durrington PN, Mackness B, Mackness MI.

Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1248-50. No abstract available.

PMID:
12171781
24.

The paraoxonase gene family and coronary heart disease.

Mackness B, Durrington PN, Mackness MI.

Curr Opin Lipidol. 2002 Aug;13(4):357-62. Review.

PMID:
12151850
25.

Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls.

Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI.

Eur J Clin Invest. 2002 Apr;32(4):259-64.

PMID:
11952811
26.

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.

Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Fuller JH; Collaborative AtoRvastatin Diabetes Study (CARDS).

Diabet Med. 2002 Mar;19(3):201-11.

PMID:
11918622
27.

Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?

Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI.

Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1451-7.

PMID:
11557671
28.

Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines.

Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH.

Nephrol Dial Transplant. 2001 Jun;16(6):1189-97.

PMID:
11390719
29.

Paraoxonase and atherosclerosis.

Durrington PN, Mackness B, Mackness MI.

Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):473-80. Review.

PMID:
11304460
31.

Hydrolysis of platelet-activating factor by human serum paraoxonase.

Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI.

Biochem J. 2001 Feb 15;354(Pt 1):1-7.

32.

Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia.

Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN.

BMJ. 2000 Dec 16;321(7275):1497-500.

33.

Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study.

Sweetnam PM, Bolton CH, Downs LG, Durrington PN, MacKness MI, Elwood PC, Yarnell JW.

Eur J Clin Invest. 2000 Nov;30(11):947-56.

PMID:
11114956
34.

Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome.

Mackness B, Durrington PN, Mackness MI.

Biochem Biophys Res Commun. 2000 Sep 24;276(2):729-33.

PMID:
11027539
35.

Still life in oxidation hypothesis of atherogenesis.

Durrington PN, Mackness MI.

Lancet. 2000 Jul 8;356(9224):165. No abstract available.

PMID:
10963272
36.

How high-density lipoprotein protects against the effects of lipid peroxidation.

Mackness MI, Durrington PN, Mackness B.

Curr Opin Lipidol. 2000 Aug;11(4):383-8. Review.

PMID:
10945720
37.

The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2).

Arrol S, Mackness MI, Durrington PN.

Atherosclerosis. 2000 Jun;150(2):255-64.

PMID:
10856517
38.
39.

Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy.

Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI.

Clin Sci (Lond). 2000 Mar;98(3):355-63.

PMID:
10677395
40.

Endothelial dysfunction in Type 1 diabetes mellitus: relationship with LDL oxidation and the effects of vitamin E.

Pinkney JH, Downs L, Hopton M, Mackness MI, Bolton CH.

Diabet Med. 1999 Dec;16(12):993-9.

PMID:
10656227
41.

Paraoxonase activity in two healthy populations with differing rates of coronary heart disease.

MacKness B, Mackness MI, Durrington PN, Arrol S, Evans AE, McMaster D, Ferrières J, Ruidavets JB, Williams NR, Howard AN.

Eur J Clin Invest. 2000 Jan;30(1):4-10.

PMID:
10619995
42.

Low serum paraoxonase: a risk factor for atherosclerotic disease?

Mackness MI, Durrington PN, Ayub A, Mackness B.

Chem Biol Interact. 1999 May 14;119-120:389-97. Review.

PMID:
10421475
43.

Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification.

Julier K, Mackness MI, Dean JD, Durrington PN.

Diabet Med. 1999 May;16(5):415-23.

PMID:
10342342
44.

Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation.

Mackness B, Durrington PN, Mackness MI.

Lancet. 1999 Feb 6;353(9151):468-9. No abstract available.

PMID:
9989726
45.

Serum paraoxonase after myocardial infarction.

Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN.

Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):330-5.

PMID:
9974415
46.

The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women.

Buckler HM, McElhone K, Durrington PN, Mackness MI, Ludlam CA, Wu FC.

Clin Endocrinol (Oxf). 1998 Aug;49(2):173-8.

PMID:
9828903
47.

Paraoxonase and coronary heart disease.

Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shih D, Fonarow GC.

Curr Opin Lipidol. 1998 Aug;9(4):319-24. Review.

PMID:
9739487
48.

Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus.

Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJ, Durrington PN.

Atherosclerosis. 1998 Aug;139(2):341-9.

PMID:
9712341
49.

Human serum paraoxonase.

Mackness B, Durrington PN, Mackness MI.

Gen Pharmacol. 1998 Sep;31(3):329-36. Review.

PMID:
9703197
50.

Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.

Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.

Atherosclerosis. 1998 May;138(1):217-25.

PMID:
9678787

Supplemental Content

Loading ...
Support Center